Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]

被引：0
|
作者：
Pennel, Elicia [1 ]
Kapp, Amy V. [1 ]
Do, An [1 ]
Tam, Rachel [1 ]
Sumiyoshi, Teiko [1 ]
Marathe, Chaitra [1 ]
Sa, Susan [1 ]
Peale, Franklin [1 ]
Lackner, Mark [1 ]
Holden, Scott [1 ]
Seiwert, Tanguy [2 ]
Pirzkall, Andrea [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
    Fayette, Jerome
    Wirth, Lori
    Oprean, Cristina
    Udrea, Anghel
    Jimeno, Antonio
    Rischin, Danny
    Nutting, Christopher
    Harari, Paul M.
    Csoszi, Tibor
    Cernea, Dana
    O'Brien, Paul
    Hanley, William D.
    Kapp, Amy V.
    Anderson, Maria
    Penuel, Elicia
    McCall, Bruce
    Pirzkall, Andrea
    Vermorken, Jan B.
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [2] Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
    Saba, Nabil F.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [3] Phase Ib Study of Duligotuzumab (MEHD7945A) Plus Cisplatin/5-Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Jimeno, Antonio
    Machiels, Jean-Pascal
    Wirth, Lori
    Specenier, Pol
    Seiwert, Tanguy Y.
    Mardjuadi, Feby
    Wang, Xiaodong
    Kapp, Amy V.
    Royer-Joo, Stephanie
    Penuel, Elicia
    McCall, Bruce
    Pirzkall, Andrea
    Clement, Paul M.
    CANCER, 2016, 122 (24) : 3803 - 3811
  • [4] Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Rosenberg, Ari J.
    Kato, Shumei
    Johnson, Daniel
    Popovtzer, Aron
    Chiu, Vi K.
    Geva, Ravit
    Ben-David, Hava
    Meirson, Tomer
    Schickler, Michael
    Reuveni, Hadas
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN)
    Glisson, Bonnie S.
    Tseng, Jennifer
    Marur, Shanthi
    Shin, Dong M.
    Murphy, Barbara A.
    Cohen, Ezra E. W.
    Thomas, Christopher Y.
    Willey, Richard
    Cosaert, Jan
    William, William Nassib
    Harun, Nusrat
    Lee, J. Jack
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
    Hill, Andrew G.
    Findlay, Michael P.
    Burge, Matthew E.
    Jackson, Christopher
    Alfonso, Pilar Garcia
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    Di Bartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew L.
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana I.
    McCall, Bruce B.
    Hanley, William D.
    Penuel, Elicia M.
    Pirzkall, Andrea
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2276 - 2284
  • [8] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Degardin, M.
    Zhang, W.
    Blackman, A.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1813 - 1820
  • [9] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [10] Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX
    Ham, J.
    Meerten, E.
    Fiets, E.
    Mc Haaglanden, F. Jeurissen
    Slingerland, M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    Beerepoot, L. V.
    ANNALS OF ONCOLOGY, 2018, 29
12345